Paper313007
The beige mutation in the mouse selectively impairs natural killer cell function.
Roder J and 1 other. Nature, 1979. Cited by 448 papers, by iCite.
Cite this record
ConductScience Library. The beige mutation in the mouse selectively impairs natural killer cell function. Papers, record 313007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/313007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cytotoxicity, Immunologic | Major topic |
| Immunity, Innate | Major topic |
| Killer Cells, Natural | Major topic |
| Mice, Mutant Strains | Major topic |
| Animals | |
| Antibody-Dependent Cell Cytotoxicity | |
| Immunologic Memory | |
| Macrophages | |
| Mice | |
| Spleen | |
| T-Lymphocytes |
Source PubMed
Cited by126
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 448 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39117835 | Murine Models of Familial Cytokine Storm Syndromes. | Adv Exp Med Biol | 2024 | https://conductscience.org/library/papers/39117835 | PubMed |
| 38544830 | Animal model considerations for chordoma research: reproducing the tumor microenvironment in vivo with humanized mice. | Front Oncol | 2024 | https://conductscience.org/library/papers/38544830 | PubMed |
| 38390969 | Xenograft and organoid models in developing precision medicine for gastric cancer (Review). | Int J Oncol | 2024 | https://conductscience.org/library/papers/38390969 | PubMed |
| 37641405 | FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment. | Mol Ther | 2023 | https://conductscience.org/library/papers/37641405 | PubMed |
| 37344821 | Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/37344821 | PubMed |
| 34837653 | The lysosomal trafficking regulator is necessary for normal wound healing. | Wound Repair Regen | 2022 | https://conductscience.org/library/papers/34837653 | PubMed |
| 33498509 | Comparison of Genetically Engineered Immunodeficient Animal Models for Nonclinical Testing of Stem Cell Therapies. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33498509 | PubMed |
| 31959757 | Distinctive phenotypes and functions of innate lymphoid cells in human decidua during early pregnancy. | Nat Commun | 2020 | https://conductscience.org/library/papers/31959757 | PubMed |
| 31412684 | Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. | Cells | 2019 | https://conductscience.org/library/papers/31412684 | PubMed |
| 30455698 | Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. | Front Immunol | 2018 | https://conductscience.org/library/papers/30455698 | PubMed |
| 29654211 | Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. | J Immunol | 2018 | https://conductscience.org/library/papers/29654211 | PubMed |
| 29654064 | Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. | Mol Cancer Ther | 2018 | https://conductscience.org/library/papers/29654064 | PubMed |
| 28025748 | Patient-derived xenograft (PDX) models in basic and translational breast cancer research. | Cancer Metastasis Rev | 2016 | https://conductscience.org/library/papers/28025748 | PubMed |
| 27835880 | Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/27835880 | PubMed |
| 27199990 | Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control. | Front Immunol | 2016 | https://conductscience.org/library/papers/27199990 | PubMed |
| 25941352 | Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. | Cancer Immunol Res | 2015 | https://conductscience.org/library/papers/25941352 | PubMed |
| 23856999 | Ischemia-reperfusion injury accelerates human antibody-mediated transplant vasculopathy. | Transplantation | 2013 | https://conductscience.org/library/papers/23856999 | PubMed |
| 22919660 | Natural killer cells in experimental and human leishmaniasis. | Front Cell Infect Microbiol | 2012 | https://conductscience.org/library/papers/22919660 | PubMed |
| 21407206 | Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. | Nat Commun | 2011 | https://conductscience.org/library/papers/21407206 | PubMed |
| 20939894 | Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. | BMC Immunol | 2010 | https://conductscience.org/library/papers/20939894 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/313007
GET https://conductscience.org/api/papers/v1/313007/cited_by?page=2